Overview

Vivex Biologics is a privately held regenerative medicine company headquartered in Miami, Florida, founded in 2014. It processes, distributes, and develops biologic products, including amniotic, bone, skin, and intervertebral disc tissue allografts, serving the medical sector. The company has an estimated 200 to 500 employees and an estimated revenue band of $10 to 50 million. In July 2026 it launched VIA Linx, a synthetic peptide matrix for advanced wound care.

At a glance

What Vivex Biologics makes

The company is ISO 9001 certified and offers allograft tissue products for wound care, orthopedic fusion, and pain management.

Products and capabilities described on the company's own site include Assembly, Transmission (source: vivex.com).

Certifications

Vivex Biologics is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:

• ISO 9001 — prnewswire.com

Latest developments

• 2026-10-28 — Vivex Biologics' VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine - VIVEX Biologics (vivex.com)

• 2026-09-10 — We’re expanding our VIA Disc NP team and looking for driven, high-performing sales leaders in three key Florida markets: | Vivex Biologics (linkedin.com)

• 2026-07-22 — Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions - VIVEX Biologics (vivex.com)

• 2026-06-05 — Vivex Biologics Publishes New Medicare Real-World Evidence Study Showing VIA Disc® NP Significantly Reduces Opioid Use, Imaging, and Conservative Care Utilization in Patients with Lumbar Discogenic Pain - VIVEX Biologics (vivex.com)

• 2026-02-12 — Vivex Announces New Peer-Reviewed Publication Demonstrating Long-Term Fusion Outcomes with VIA Form+™ in Lumbar Interbody Fusion - VIVEX Biologics (vivex.com)

• 2025-09-30 — Vivex Biologics Treats First Patient in its Restore Trial (globenewswire.com)

Facilities

Vivex Biologics is headquartered in Miami, Florida. Public sources also reference these locations:

• Miami, Florida — stantec.com

Company details

Vivex Biologics is privately held, with an estimated revenue band of $10 to 50 million and an estimated workforce of 200 to 500 employees. Vivex Biologics was founded in 2014, has an estimated 200-500 employees, and is headquartered in Miami, Florida. On the LightSource stability read it is rated "Established & active": 12 years in operation (founded 2014). Holds ISO 9001 certification(s) per public sources.

Frequently asked questions

What does Vivex Biologics make?

Vivex Biologics is a privately held regenerative medicine company headquartered in Miami, Florida, founded in 2014. It processes, distributes, and develops biologic products, including amniotic, bone, skin, and intervertebral disc tissue allografts, serving the medical sector. The company has an estimated 200 to 500 employees and an estimated revenue band of $10 to 50 million. In July 2026 it launched VIA Linx, a synthetic peptide matrix for advanced wound care.

Where is Vivex Biologics headquartered?

Vivex Biologics is headquartered in Miami, Florida (2430 NW 116th St, Miami, Florida, 33167-0001).

When was Vivex Biologics founded?

Vivex Biologics was founded in 2014.

How big is Vivex Biologics?

Vivex Biologics has an estimated 200-500 employees, with revenue in the $10-50M range (estimated).

What certifications does Vivex Biologics hold?

Vivex Biologics lists ISO 9001 on its website. Confirm the certified scope for the specific plant producing your part.

Related suppliers

Explore other suppliers in the LightSource directory:

• ACDelco

• AerSale, Inc.

• Aisin Automotive Casting, LLC

• Allison Transmission

• AMBAC International

Last verified Nov 2026. Is this your company? Request a correction.